Intensity Therapeutics (INTS) Share-based Compensation (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Share-based Compensation came in at $387000.0 in Q1 2026, down 11.03% YoY from $435000.0 in Q1 2025, and up 135.87% on a QoQ basis from -$1.1 million in Q3 2025.
Intensity Therapeutics (INTS) Share-based Compensation (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Share-based Compensation data on file, last reported at $387000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 11.03% year-over-year to $387000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$48000.0 (down 102.04% YoY) and the FY2024 annual result came in at $3.1 million, down 35.13% from the prior year.
- Share-based Compensation climbed to $387000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q4 2023 to a low of -$1.7 million in Q3 2024.
- A 5-year average of $604701.3 and a median of $387000.0 in 2026 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation jumped 3862.16% — and 2024, when it sank 215.62%.
- Tracing INTS's Share-based Compensation over 5 years: stood at -$430000.0 in 2022, then surged by 974.88% to $3.8 million in 2023, then decreased by 19.67% to $3.0 million in 2024, then sank by 135.7% to -$1.1 million in 2025, then surged by 135.87% to $387000.0 in 2026.
- The last three Share-based Compensation figures came in at $387000.0 (Q1 2026), -$1.1 million (Q3 2025), and $644000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Intensity Therapeutics | 12.56 Mn | 12.56 Mn | - | 387,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 387,000.00 |
| Jun 30, 2026 | 387,000.00 |
| Mar 31, 2026 | 387,000.00 |
| Mar 31, 2026 | 387,000.00 |
| Sep 30, 2025 | -1.08 Mn |
| Sep 30, 2025 | -1.08 Mn |
| Jun 30, 2025 | 644,000.00 |
| Jun 30, 2025 | 644,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Dec 31, 2024 | 3.02 Mn |
| Dec 31, 2024 | 3.02 Mn |
| Sep 30, 2024 | -1.70 Mn |
| Sep 30, 2024 | -1.70 Mn |
| Jun 30, 2024 | 591,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 3.76 Mn |
| Dec 31, 2023 | 3.76 Mn |